Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives $48.00 Average Price Target from Brokerages

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) have earned an average recommendation of “Hold” from the seven research firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $48.00.

A number of equities research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Citigroup assumed coverage on Sensei Biotherapeutics in a research note on Friday, May 22nd. They set a “buy” rating and a $55.00 price objective for the company. Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Finally, Loop Capital set a $50.00 target price on Sensei Biotherapeutics in a research report on Thursday, May 28th.

Sensei Biotherapeutics Stock Up 2.1%

Shares of NASDAQ SNSE opened at $14.15 on Tuesday. Sensei Biotherapeutics has a fifty-two week low of $5.86 and a fifty-two week high of $36.76. The business has a 50 day moving average price of $21.22 and a two-hundred day moving average price of $19.16. The firm has a market cap of $18.98 million, a PE ratio of -0.10 and a beta of -0.25.

Sensei Biotherapeutics (NASDAQ:SNSE) last issued its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($130.83).

Insider Activity at Sensei Biotherapeutics

In other news, major shareholder Millennium Management Llc bought 15,321 shares of the firm’s stock in a transaction dated Friday, March 27th. The stock was bought at an average price of $26.61 per share, for a total transaction of $407,691.81. Following the transaction, the insider owned 142,360 shares in the company, valued at $3,788,199.60. The trade was a 12.06% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the completion of the transaction, the insider owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. The trade was a 16.11% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders bought 46,980 shares of company stock valued at $1,341,669 and sold 48,067 shares valued at $1,204,939. 7.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in SNSE. Renaissance Technologies LLC grew its position in shares of Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock worth $123,000 after acquiring an additional 1,100 shares in the last quarter. Bank of America Corp DE grew its position in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after acquiring an additional 32,719 shares in the last quarter. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. Finally, Vivo Capital LLC acquired a new position in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.